Evolution from adherent to suspension: systems biology of HEK293 cell line development
Artikel i vetenskaplig tidskrift, 2020

The need for new safe and efficacious therapies has led to an increased focus on biologics produced in mammalian cells. The human cell line HEK293 has bio-synthetic potential for human-like production attributes and is currently used for manufacturing of several therapeutic proteins and viral vectors. Despite the increased popularity of this strain we still have limited knowledge on the genetic composition of its derivatives. Here we present a genomic, transcriptomic and metabolic gene analysis of six of the most widely used HEK293 cell lines. Changes in gene copy and expression between industrial progeny cell lines and the original HEK293 were associated with cellular component organization, cell motility and cell adhesion. Changes in gene expression between adherent and suspension derivatives highlighted switching in cholesterol biosynthesis and expression of five key genes (RARG, ID1, ZIC1, LOX and DHRS3), a pattern validated in 63 human adherent or suspension cell lines of other origin.

Författare

Magdalena Malm

Kungliga Tekniska Högskolan (KTH)

Rasool Saghaleyni

Chalmers, Biologi och bioteknik, Systembiologi

Magnus Lundqvist

Kungliga Tekniska Högskolan (KTH)

Marco Giudici

Kungliga Tekniska Högskolan (KTH)

Veronique Chotteau

Kungliga Tekniska Högskolan (KTH)

Ray Field

AstraZeneca AB

GammaDelta Therapeutics Ltd

Paul G. Varley

AstraZeneca AB

Kymab Limited

Diane Hatton

AstraZeneca AB

Luigi Grassi

AstraZeneca AB

Thomas Svensson

Chalmers, Biologi och bioteknik, Systembiologi

Jens B Nielsen

Danmarks Tekniske Universitet (DTU)

Chalmers, Biologi och bioteknik, Systembiologi

J. Rockberg

Kungliga Tekniska Högskolan (KTH)

Scientific Reports

2045-2322 (ISSN) 20452322 (eISSN)

Vol. 10 1 18996

Ämneskategorier

Cellbiologi

Cell- och molekylärbiologi

Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci)

DOI

10.1038/s41598-020-76137-8

PubMed

33149219

Mer information

Senast uppdaterat

2020-11-12